United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $539.99, for a total value of $5,129,905.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $175,195,975.57. This trade represents a 2.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Price Performance

UTHR opened at $541.51 on Friday. The stock has a market cap of $23.23 billion, a P/E ratio of 19.37, a P/E/G ratio of 3.86 and a beta of 0.49. The stock’s 50 day simple moving average is $513.75 and its 200 day simple moving average is $540.45. United Therapeutics Corporation has a 1-year low of $409.07 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period last year, the business posted $6.41 EPS. Research analysts expect that United Therapeutics Corporation will post 26.40 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in United Therapeutics during the 2nd quarter valued at $2,868,735,000. Jupiter Topco LLC purchased a new position in United Therapeutics during the second quarter worth $450,140,000. Bank of New York Mellon Corp purchased a new position in United Therapeutics during the second quarter worth $159,522,000. Caisse de depot et placement du Quebec purchased a new position in United Therapeutics during the second quarter worth $154,304,000. Finally, Legal & General Group Plc acquired a new position in shares of United Therapeutics in the second quarter worth $112,209,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley boosted their price objective on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $368.00 target price on shares of United Therapeutics in a report on Thursday. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $642.69.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics settled all six patent and antitrust disputes with Liquidia, reducing litigation uncertainty surrounding Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement also limits YUTREPIA’s label, particularly by excluding the pulmonary hypertension associated with interstitial lung disease indication, which may protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
• Positive Sentiment: The settlement calls for Liquidia to make approximately $380.7 million in payments, providing United Therapeutics with financial compensation for resolving the disputes. The deal also gives investors more visibility into the future competitive landscape. LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
• Positive Sentiment: Jefferies raised its price target for United Therapeutics to $728. Other analysts also remain constructive: the stock carries a “Moderate Buy” consensus rating and an average target of $627.31, above the recent trading level. UTHR Price Target Raised to $728 at Jefferies
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her ownership by 2.84%. The transaction was disclosed in an SEC filing, but the remaining stake is substantial and the sale alone does not establish a change in business outlook. United Therapeutics CEO Stock Sale SEC Filing

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.